A Phase I/Ii Trial of Transurethral Surgery Combined With Concurrent Cisplatin, 5-Fluorouracil and Twice Daily Radiation Followed by Selective Bladder Preservation in Operable Patients With Muscle Invading Bladder Cancer

Abstract

This pilot study demonstrates a high rate of response to this combined chemotherapy/radiation regimen in conjunction with a visibly complete transurethral resection. Reevaluation after a short induction phase allows for the early selection of patients with persistent disease for radical cystectomy.

The Relation between Survivin Gene Expression and Urinary Bladder Cancer Disease

“…While small cell carcinoma as well as squamous cell carcinoma each of them constituted 3.85% (1 case per each type). This is was similar to results reported by Lynch et al 3 who stated that most of the tumors 72.0% were transitional cell carcinomas and 22.0% were adenocarcinomas.3 From the present study it was noticed that most of the patients (16 patients, 61.54% ) had tumors with grade III ( 5 patients ,19.23 %) had tumors with grade II, and (5 patients,19.23%) had grade I, However our data was close to Rodel et al 23 where high grade tumors represented 57.8% only, 23 However, that was different from Zietman et al 20 who found that high grade tumors represent 77.7%, and also different from Zapatero et al,22 who reported that 94% of the tumors were of high grade. 20,22 The present study showed that 9 patients (34.61 %) had T3 disease, while T2 disease was seen in 8 patients (30.77%), 7patients (26.9%) had T4 disease and 2 patients (7.69%) with T1 disease stage, this result is consistent with the disease stage reported by Shariat et al 25 who noticed that most of the patients (36,5%) had T3 disease, but different in the percent of other patient disease stages.…”

“…However, the median age of 63 years (range 42-75) was reported by Zietman et al, 22 and a median age of 63 years (range 31-79) reported by Rodel et al 23 From the present study it was noticed that males were more affected than females, 22 males (84.61%) and 4 females (15.38%) this results is closely related to the previous results of the data reported by Tonoli et al, 24 where males represent 86% of the whole series and Gupta et al 21 who found that the male to female ratio was 8.6:1.…”

“…20,22 The present study showed that 9 patients (34.61 %) had T3 disease, while T2 disease was seen in 8 patients (30.77%), 7patients (26.9%) had T4 disease and 2 patients (7.69%) with T1 disease stage, this result is consistent with the disease stage reported by Shariat et al 25 who noticed that most of the patients (36,5%) had T3 disease, but different in the percent of other patient disease stages. However, this was different from the disease stage reported by Kaufman et al 26 where T2 disease constituted 88% and T3 disease constituted 12% of the entire patient population.…”

Acridine Orange Excited by Low-Dose Radiation Has a Strong Cytocidal Effect on Mouse Osteosarcoma

“…Based on these results, we hypothesized that AO could be excited by X-ray irradiation. Many anti-cancer drugs which show a radiation enhancement effect have been reported previously, and these include mitomycin C [42, 43], bleomycin [44, 45], doxorubicin [46], methotrexate [47], 5-fluorouracil and cisplatin [48, 49]. Although possible mechanisms of enhancement have been reported [50], the exact mechanism is still unclear.…”

Phase 1/2 Study of Synchronous Methotrexate, Cisplatin, Vincristine (MOPq10) Chemotherapy and Radiation for Patients with Locally Advanced Bladder Cancer

“…Table 3 summarises the response to treatment as assessed by cystoscopy at 3 and 12 months. 88% were RT + TURB [23] 296 Urol Int 2001;67:293-297 Goonewardene/Bozcuk/Oliver/Barua/ Nargund/Philip/Mair/Gibbs [4] 171 48 RT and concurrent cisplatin and TURB [18] 145 72 5FU, MMC and RT [20] 20 70 5FU and cisplatin and RT [19] 18 70 5FU and cisplatin and RT [21] 25 88 RT and concurrent MOPq10 and TURB (this report) 17 88 RT = Radiotherapy; TURB = transurethral resection of the bladder.…”